Actinium Pharmaceuticals (Delaware) (ATNM) vs BriaCell Therapeutics (BCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed BriaCell Therapeutics (BCTX) over the past year, losing 29.9% versus a loss of 69.2%. Over five years, ATNM leads with a -86.6% price change compared with -95.2% for BCTX. BriaCell Therapeutics is the larger company by market cap ($34.5 million vs $34.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | BCTX |
|---|---|---|
| Share price | $1.09 | $3.97 |
| Market cap | $34.27M | $34.49M |
| 1-day change | +0.93% | +1.28% |
| YTD return | -20.59% | -44.87% |
| 1-year return | -29.87% | -69.18% |
| 5-year return | -86.57% | -95.21% |
| P/E ratio (TTM) | 3.03 | — |
| EPS (TTM) | $0.36 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.74 | $14.68 |
| 52-week low | $0.735 | $2.60 |
| Distance from 52-week high | -37.36% | -72.99% |
| Analyst consensus | none | — |
| Avg. price target upside | +230.28% | — |
| Average volume | 139.78K | 278.91K |
| Shares outstanding | 31.44M | 8.70M |
| Employees | 27 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed BCTX by 39.3 percentage points over the past year.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations
ATNM vs BCTX FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or BriaCell Therapeutics?
BriaCell Therapeutics (BCTX) is larger, with a market capitalization of $34.49M compared with $34.27M for Actinium Pharmaceuticals (Delaware) (ATNM).
Which stock has performed better over the past year, ATNM or BCTX?
ATNM returned -29.87% over the past 12 months, compared with -69.18% for BCTX (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and BriaCell Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.